Is Iovance Biotherapeutics, Inc. overvalued or undervalued?

As of 28 February 2024, the valuation grade for Iovance Biotherapeutics, Inc. has moved from does not qualify to risky. The company is currently assessed as overvalued. Key ratios include a Price to Book Value of 0.89, an EV to Sales ratio of 1.57, and a ROCE of -95.61%.
In comparison to its peers, Iovance's valuation metrics are concerning, with Summit Therapeutics, Inc. showing a significantly lower P/E of -65.30 and Merus NV at -14.25, indicating that Iovance is not only underperforming but also carries higher risk. The company's recent stock performance has been poor, with a year-to-date return of -75.00%, contrasting sharply with the S&P 500's gain of 2.44%, further reinforcing the notion that Iovance is overvalued in its current state.